Author: Zhenhua Zeng; Tong Sha; Yuan Zhang; Feng Wu; Hongbin Hu; Haijun Li; Jiafa Han; Wenhong Song; Qiaobing Huang; Zhongqing Chen
Title: Hypertension in patients hospitalized with COVID-19 in Wuhan, China: A single-center retrospective observational study Document date: 2020_4_11
ID: lujxql3a_8
Snippet: Clinical outcomes were followed up to March 8, 2020. To analyze the relationship between stage of hypertension and clinical outcome, a minimum follow-up time of 14 days was required, including follow-up of patients who were discharged before March 8, 2020. If data were missing from the records or clarification was needed, the researchers also directly communicated with patients or their families to ascertain epidemiological and symptom data. All .....
Document: Clinical outcomes were followed up to March 8, 2020. To analyze the relationship between stage of hypertension and clinical outcome, a minimum follow-up time of 14 days was required, including follow-up of patients who were discharged before March 8, 2020. If data were missing from the records or clarification was needed, the researchers also directly communicated with patients or their families to ascertain epidemiological and symptom data. All data were checked by two physicians (TS and HH). Initial investigations included a complete blood count, coagulation profile, and serum biochemical test (including renal and liver function, creatine kinase, lactate dehydrogenase (LDH), electrolytes, and 10 common respiratory pathogens). A description of the treatment procedures and measurements has been . CC-BY-ND 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
Search related documents:
Co phrase search for related documents- biochemical test and cc ND international license: 1
- biochemical test and clinical outcome: 1, 2, 3
- biochemical test and coagulation profile: 1, 2, 3, 4
- biochemical test and complete blood count: 1, 2, 3, 4, 5, 6, 7
- biochemical test and creatine kinase: 1, 2, 3, 4, 5, 6
- blood count and cc ND international license: 1, 2, 3, 4, 5, 6, 7
- blood count and clinical outcome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- blood count and clinical outcome hypertension: 1
- blood count and coagulation profile: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13
- blood count and complete blood count: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- blood count and creatine kinase: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
- blood count and family patient: 1
- blood count and initial investigation: 1
- cc ND international license and clinical outcome: 1, 2, 3, 4, 5, 6, 7
- cc ND international license and coagulation profile: 1, 2, 3
- cc ND international license and complete blood count: 1, 2, 3
- cc ND international license and creatine kinase: 1, 2, 3, 4
- cc ND international license and family patient: 1
- clinical outcome and family patient: 1, 2, 3, 4, 5, 6
Co phrase search for related documents, hyperlinks ordered by date